Related Experiment Video
Updated: Jun 21, 2026
07:01
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
CD133 antigen expression in ovarian cancer
Gabriella Ferrandina1, Enrica Martinelli, Marco Petrillo
1Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy. gabriella.ferrandina@libero.it
BMC Cancer
|July 9, 2009
Summary
CD133 expression in ovarian cancer did not correlate with patient prognosis. Further studies are needed to investigate the role of different CD133 expression patterns in cancer stem cells.
Area of Science:
- Oncology
- Immunohistochemistry
- Cancer Stem Cell Biology
Background:
- Cancer stem cells (CSCs) drive tumor initiation and progression.
- CD133 is a marker for stemness features in various malignancies.
- Identifying CSCs via antigenic profiles has clinical implications.
Purpose of the Study:
- To investigate the clinical significance of CD133 expression in ovarian cancer.
- To assess CD133's prognostic value using immunohistochemistry.
Main Methods:
- Analyzed 160 ovarian cancer patient cases.
- Used anti-CD133-1 antibody for immunohistochemical detection.
- Correlated CD133 expression with patient outcomes (TTP, OS).
Main Results:
- CD133 positive tumor cells found in 31.2% of cases.
- No significant difference in Time to Progression (TTP) or Overall Survival (OS) between CD133 positive and negative cases.
- A trend towards worse prognosis with diffuse cytoplasmic CD133 pattern, but not statistically significant.
Conclusions:
- Immunohistochemical assessment of CD133 does not appear to offer additional prognostic information in ovarian cancer.
- Further research with larger cohorts is warranted to explore the prognostic role of CD133 expression patterns.
